4D Molecular Therapeutics (FDMT) Interest Expenses (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Interest Expenses data on file, last reported at $26.2 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 1768.21% year-over-year to $26.2 million in Q1 2026; TTM through Mar 2026 was $26.2 million, a 570.64% increase from a year earlier, with the FY2025 full-year figure at $158.6 million, up 23.79% from the prior year.
• Interest Expenses for Q1 2026 stood at $26.2 million, up from $1.4 million in the prior quarter.
• Over the last five years, Interest Expenses for FDMT reached as high as $34.1 million in Q3 2024 and fell as low as $800000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $13.1 million across 5 years, with a median of $5.7 million in 2022.
• Across the five-year window, Interest Expenses slumped 96.02% in 2024 and surged 1768.21% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $2.9 million in 2022, then slumped by 72.41% to $800000.0 in 2023, then gained by 12.5% to $900000.0 in 2024, then jumped by 55.56% to $1.4 million in 2025, then jumped by 1768.21% to $26.2 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $26.2 million in Q1 2026, $1.4 million in Q4 2025, and $29.0 million in Q3 2025.